Literature DB >> 9433870

Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors.

J Braun1, M Bollow, G Remlinger, U Eggens, M Rudwaleit, A Distler, J Sieper.   

Abstract

OBJECTIVE: To determine the overall prevalence of spondylarthropathy (SpA) among whites.
METHODS: To screen for SpA symptoms, such as inflammatory back pain (IBP), joint swelling, psoriasis, and uveitis, or a specific family history, questionnaires were mailed to 348 blood donors (174 HLA-B27 positive and 174 HLA-B27 negative). From the responding 273 persons (78%; 140 B27 positive, 133 B27 negative), 126 were selected for further evaluation based on the symptoms reported. Of this group, 90 persons agreed to undergo physical examination (71.4%; 46 B27 positive, 44 B27 negative). There was no difference between the B27-positive and -negative groups in terms of age (mean +/- SD 38.4 +/- 10 versus 39.5 +/- 11 years) and sex ratio (67% versus 68% were men). In addition, 58 donors (32 B27 positive, 26 B27 negative) agreed to undergo magnetic resonance imaging (MRI) of the sacroiliac joints. A diagnosis of SpA and ankylosing spondylitis (AS) was made according to the European Spondylarthropathy Study Group criteria and the New York criteria.
RESULTS: SpA was diagnosed in 20 persons: 19 of 140 B27-positive (13.6%) and 1 of 133 B27-negative (0.7%) subjects (15 male and 5 female). AS was diagnosed in 9 persons (7 male and 2 female; 45%), undifferentiated SpA (USpA) in 7 (5 male and 2 female; 35%), psoriatic arthritis (PsA) in 3 (2 male and 1 female; 15%), and chronic reactive arthritis (ReA; Reiter's syndrome) in 1 (male; 5%). On the basis of a B27 frequency of 9.3% among the population of Berlin (3.47 million persons), the estimated prevalence of SpA was 1.9%, AS was 0.86%, USpA was 0.67%, and PsA was 0.29%. The relative risk of developing SpA in B27-positive subjects was calculated as 20.7 (95% confidence interval 4.6-94.2; P = 0.001). Of 58 persons with IBP, sacroiliitis was detected by MRI in 15 of 32 B27-positive (46.9%) and 1 of 26 B27-negative (3.9%) subjects (P = 0.002). Four of these 16 donors did not fulfill diagnostic criteria for SpA.
CONCLUSION: With a calculated prevalence of 1.9%, spondylarthropathies are among the most frequent rheumatic diseases in the white population. HLA-B27 positive persons carry a 20-fold increased risk of developing SpA. AS and USpA are the most frequent SpA subtypes. Persons with IBP who are B27 positive have a 50% likelihood of having sacroiliitis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9433870     DOI: 10.1002/1529-0131(199801)41:1<58::AID-ART8>3.0.CO;2-G

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  263 in total

1.  Recurrence risk modelling of the genetic susceptibility to ankylosing spondylitis.

Authors:  M A Brown; S H Laval; S Brophy; A Calin
Journal:  Ann Rheum Dis       Date:  2000-11       Impact factor: 19.103

Review 2.  Treatment of spondyloarthropathies with antibodies against tumour necrosis factor alpha: first clinical and laboratory experiences.

Authors:  J Braun; J Xiang; J Brandt; H Maetzel; H Haibel; P Wu; S Kohler; M Rudwaleit; S Siegert; A Radbruch; A Thiel; J Sieper
Journal:  Ann Rheum Dis       Date:  2000-11       Impact factor: 19.103

Review 3.  New treatment options in ankylosing spondylitis: a role for anti-TNFalpha therapy.

Authors:  J Sieper; J Braun
Journal:  Ann Rheum Dis       Date:  2001-11       Impact factor: 19.103

4.  Infection and work stress are potential triggers of ankylosing spondylitis.

Authors:  Jane Zochling; Martin H J Bohl-Bühler; Xenofon Baraliakos; Ernst Feldtkeller; Jürgen Braun
Journal:  Clin Rheumatol       Date:  2006-04-22       Impact factor: 2.980

Review 5.  International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis.

Authors:  J Braun; T Pham; J Sieper; J Davis; Sj van der Linden; M Dougados; D van der Heijde
Journal:  Ann Rheum Dis       Date:  2003-09       Impact factor: 19.103

6.  Unusual association of systemic sclerosis and ankylosing spondylitis.

Authors:  Cinira S Soledade; Percival D Sampaio-Barros; Adil M Samara; João Francisco Marques-Neto
Journal:  Clin Rheumatol       Date:  2004-08-27       Impact factor: 2.980

7.  Analysing chronic spinal changes in ankylosing spondylitis: a systematic comparison of conventional x rays with magnetic resonance imaging using established and new scoring systems.

Authors:  J Braun; X Baraliakos; W Golder; K-G Hermann; J Listing; J Brandt; M Rudwaleit; S Zuehlsdorf; M Bollow; J Sieper; D van der Heijde
Journal:  Ann Rheum Dis       Date:  2004-04-05       Impact factor: 19.103

Review 8.  HLA-B27-associated reactive arthritis: pathogenetic and clinical considerations.

Authors:  Inés Colmegna; Raquel Cuchacovich; Luis R Espinoza
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

9.  Increased risk of stroke among patients with ankylosing spondylitis: a population-based matched-cohort study.

Authors:  Joseph J Keller; Jung-Lung Hsu; Shiue-Ming Lin; Chia-Chi Chou; Li-Hsuan Wang; Jui Wang; Chyi-Huey Bai; Hung-Yi Chiou
Journal:  Rheumatol Int       Date:  2013-12-10       Impact factor: 2.631

Review 10.  Cost effectiveness of therapeutic interventions in ankylosing spondylitis: a critical and systematic review.

Authors:  Cécile Gaujoux-Viala; Bruno Fautrel
Journal:  Pharmacoeconomics       Date:  2012-12-01       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.